Aug. 17 at 5:14 AM
$ACHV Since becoming CEO of Achieve Life Sciences, Dr. Andrew Goldberg has executed a blueprint nearly identical to the playbook that turned Verona Pharma into an
$10.8B Merck acquisition. Central to this strategy is a single-asset focus, channeling all capital into de-risking cytisinicline for smoking/vaping cessation—a massive primary care market lacking novel treatments for decades, mirroring Verona’s laser focus on ensifentrine (Ohtuvayre) for COPD. Operationally, Goldberg is driving Achieve's transition to a commercial-ready enterprise by building out U.S. regulatory filings, supply chains, and market prep to prime the company for Big Pharma integration. Crucially, Achieve’s recent use of an At-the-Market (ATM) equity facility mirrors Verona's strategy: tapping flexible tranches opportunistically to extend cash runway through FDA review and fund launch prep without dilutive block discounts, maintaining maximum balance sheet leverage for ongoing partnership and buyout negotiations.
